Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

October 29, 2027

Study Completion Date

October 30, 2028

Conditions
Pancreatic Cancer
Interventions
DEVICE

Directional Brachytherapy Source Implant

The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.

Trial Locations (6)

19111

COMPLETED

Fox Chase Cancer Center, Philadelphia

23298

COMPLETED

Virginia Commonwealth University Massey Cancer Center, Richmond

33612

NOT_YET_RECRUITING

Tampa General Hospital, Tampa

60453

RECRUITING

Advocate Christ Medical Center, Oak Lawn

60612

COMPLETED

Rush University Cancer Center, Chicago

70112

COMPLETED

University Medical Center LSU, New Orleans

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CivaTech Oncology

INDUSTRY